TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Summary

This is a clinical study of ytaa05 cell injection in the treatment of patients with recurrent / refractory acute myeloid leukemia.The purpose is to evaluate the safety and preliminary efficacy of FLT3 car-t cells in patients with recurrent / refractory FLT3 positive acute myeloid leukemia.#TAA05 cell injection is a T cell targeting FLT3 chimeric antigen receptor#

Timeline

Start

2021-07-01

Primary completion

2023-10

Completion

2025-10

Drugs

Indications